Your browser doesn't support javascript.
loading
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe, Teruki; Naiki, Taku; Sugiyama, Yosuke; Naiki-Ito, Aya; Nagai, Takashi; Etani, Toshiki; Nozaki, Satoshi; Iida, Keitaro; Noda, Yusuke; Shimizu, Nobuhiko; Tomiyama, Nami; Banno, Rika; Kubota, Hiroki; Hamamoto, Shuzo; Ando, Ryosuke; Kawai, Noriyasu; Yasui, Takahiro.
Afiliação
  • Isobe T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Naiki T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan. naiki@med.nagoya-cu.ac.jp.
  • Sugiyama Y; Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
  • Naiki-Ito A; Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
  • Nagai T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Etani T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Nozaki S; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Iida K; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Noda Y; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Shimizu N; Department of Urology, Toyota Kosei Hospital, Toyota City, Japan.
  • Tomiyama N; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Banno R; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Kubota H; Department of Urology, Konan Hospital, Konan City, Japan.
  • Hamamoto S; Department of Urology, Kainan Hospital, Yatomi City, Japan.
  • Ando R; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Kawai N; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
  • Yasui T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku 467-8601, Nagoya, Japan.
Int J Clin Oncol ; 27(1): 165-174, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34633579
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Anticorpos Monoclonais Humanizados Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Anticorpos Monoclonais Humanizados Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article